Histone Deacetylase Inhibitors Market (Class - Class I HDACs, Class II HDACs, and Class III HDACs; Applications - Neurology, Oncology, Central Nervous System Disorders, and Other Diseases): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : November, 2019

  • Rep Id : HC0762

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on histone deacetylase inhibitors market provides in-depth analysis of segments and sub-segments in the global as well as regional histone deacetylase inhibitors market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional histone deacetylase inhibitors market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global histone deacetylase inhibitors market. According to the report, the global histone deacetylase inhibitors market is projected to grow at a CAGR of 5.9% over the forecast period of 2019-2025.


Market Insight

Histone deacetylase inhibitors are chemical compounds that inhibit deacetylases. Histone deacetylase inhibitors have potential applications in prognosis, treatment, and diagnosis of cancer. Mergers and acquisitions are the key strategies used by market players. In 2019, Shenzhen Chipscreen Biosciences Co. Ltd. had a strategic partnership with Novogene. The partnership stimulates the efficiency and success rate of drug development and promotes effective and more personalized treatment.


The rising prevalence of cancer globally is a major factor leading to the growth of the histone deacetylase inhibitors market. As per the World Health Organization, around 9.6 million deaths occurred in 2018 due to cancer. The surge in demand for improved and effective therapies to treat cancer and other diseases drives the growth of market. Histone deacetylase (HDAC) enzyme removes the acetyl group from histone proteins on DNA and makes the DNA less accessible to transcription factors. The high affinity and specificity of the HDAC enzyme will augment the expansion of the histone deacetylase inhibitors market. In addition, growing awareness about cancer and the growing number of clinical trials for different oncological applications stimulates the growth of histone deacetylase inhibitors market. On the other side, uncertainty and reimbursement issues with respect to HDAC inhibitors hinder the market growth. Moreover, the surge in investments in HDAC manufacturing and growing research and development activities in HDACs creates numerous opportunities for the growth of the histone deacetylase inhibitors market.


North America region is anticipated to hold a premium share in the global histone deacetylase inhibitors market owing to the growing number of research and development activities and rapid technological advancement. Europe is expected to grow in the global histone deacetylase inhibitors market with a significant CAGR over the forecast period. The rapid adoption of advanced therapeutics and well-established healthcare infrastructure in Europe led to the market’s growth. Asia-Pacific is has a significant growth rate in the global histone deacetylase inhibitors market. The increasing healthcare infrastructure and rise in the number of cancer patients in the Asia-Pacific region drive the growth of histone deacetylase inhibitors market in Asia-Pacific. The prevalence of cancer cases in Asia-Pacific is expected to increase to 70% by 2030.

Segment Covered

The report on global histone deacetylase inhibitors market covers segments such as class, and applications. On the basis of class, the sub-markets include class I HDACs, class II HDACs, and class III HDACs. On the basis of applications, the sub-markets include neurology, oncology, central nervous system disorders, and other diseases.


Companies Profiled:

The report provides profiles of the companies in the market such as Novartis International AG, Celgene Corporation, AstraZeneca plc, Acetylon Pharmaceuticals, Inc., FORUM Pharmaceuticals, Inc., Celleron Therapeutics Ltd., Merck & Co., Inc., Spectrum Pharmaceuticals, Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Oncolys BioPharma Inc., and other companies.


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the histone deacetylase inhibitors market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount